Navigation Links
Arthritis drug can prolong life

Rheumatoid arthritis strikes about 1 percent of people, usually in middle age. People with the disease tend to die about 10 years sooner than normal. It is not the type of arthritis common in the elderly because// of the wear-and-tear of aging. It occurs when the immune system goes awry and attacks the joints, causing severe inflammation in the lining of the joints, pain and stiffness. It is also linked to an increased risk of heart disease.

Methotrexate, a key drug for rheumatoid arthritis, could help people with the crippling disease live longer, possibly by decreasing their risk of heart disease. Researchers says that the study supports the growing evidence that inflammation might play a role in heart attacks and that anti-inflammatory medication might ward them off.

Originally a cancer drug, methotrexate has been used to fight rheumatoid arthritis for about 15 years. Since then it has been proven to slow progression of the inflammatory disease and to make patients feel better, but a new study provides the first hint it may also save lives.

Scientists believe people with rheumatoid arthritis have shorter life spans partly because they face increased chances of getting heart disease and dying from it. The latest study found that patients on methotrexate were 60% less likely to die prematurely than those not getting the drug.
'"/>




Page: 1

Related medicine news :

1. Another ray of hope for Arthritis Sufferers
2. Naked DNA Vaccination May Conquer Arthritis and Multiple Sclerosis
3. B Vitamin protects and lowers toxicity of Arthritis Drug
4. FDA Approves New Arthritis Drug, Bextra
5. Risk Of Developing Arthritis
6. Arthritis Drug May Cause Liver Damage
7. New treatment for Rheumatoid Arthritis
8. Important cause of Arthritis
9. Personality Impacts Arthritis
10. New Rheumatoid Arthritis Treatment
11. New Rheumatoid Arthritis Treatment
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/24/2017)... ... ... As part of the nationwide Days of Remembrance effort led by the United ... persecution, Center for Medicine after the Holocaust (CMATH) announced that it will ... and Poland next week. , The Fourth Biennial CMATH Champions Trip to Germany and ...
(Date:4/24/2017)... ... , ... Today, Bright Pink , a national non-profit organization focusing on the prevention and ... , Bright Pink is proud to announce Katie Thiede as their new Chief Executive Officer. ... as Chairman of the Board and launched a national search to find a visionary ...
(Date:4/24/2017)... ... April 24, 2017 , ... Veteran Theresa James awoke to the ... life forever. , In “Healing Tears,” James depicts every parent’s worst nightmare, when her ... I began journaling conversations and situations throughout my divorce,” James said. “After the death ...
(Date:4/24/2017)... ... 2017 , ... The world-class designers of Happy Gadget Alert ... lifesaving device for the everyday use of parents worldwide. It is a lightweight, ... a child’s vital signs, and detect unusual symptoms or physical patterns. This innovative ...
(Date:4/24/2017)... ... April 24, 2017 , ... symplrTM, a leading provider of ... that Kyle Allain has joined the company as Vice President and General Manager ... provider, payor and managed care solutions. , A seasoned executive with more ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 19, 2017 Global Prostate Cancer Therapeutics ... the prostate cancer therapeutics market analyzes the current ... prevalence of prostate cancer, launch of promising emerging ... of new drugs & therapeutic biological products, and ... to lesser side effects are some of the ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, Inc. ... clinical-stage biopharmaceutical company developing new treatments for cancer ... closing of its previously announced underwritten public offering ... a public offering price of $2.00 per share, ... offering expenses payable by Sorrento.  The net proceeds ...
(Date:4/19/2017)... , April 19, 2017  Novartis today announced ... National Heart, Lung, and Blood Institute (NHLBI) of ... 58% of patients with treatment-naïve severe aplastic anemia ... treated with eltrombopag at the initiation of and ... study evaluated three sequential treatment groups, or cohorts. ...
Breaking Medicine Technology: